Statins and atherosclerosis. Role of Rho/Rho-kinase and activation of Akt;Le statine in patologia cardiovascolare. Ruolo dell'inibizione della Rho/Rho-chinasi e dell'attivazione di Akt

Recenti Progressi in Medicina

Volumn 94, Issue 10, 2003, Pages 444-450

  Cosentino, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute coronary syndromes; Akt; Atherosclerosis; Endothelium; Inhibition of Rho Rho kinase; Intracellular signaling; Statins; Thrombosis

Indexed keywords

ATORVASTATIN; BLOOD CLOTTING FACTOR 7; CHOLESTEROL; CLOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PLATELET DERIVED GROWTH FACTOR; PRAVASTATIN; PROTEIN KINASE B; RHO FACTOR; RHO KINASE; SIMVASTATIN; THROMBOPLASTIN; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CHOLESTEROL METABOLISM; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; PRIMARY PREVENTION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; THROMBOGENESIS; VASCULAR ENDOTHELIUM;

ACUTE DISEASE; ANTICHOLESTEREMIC AGENTS; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; CORONARY THROMBOSIS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SYNDROME;

EID: 0142152714     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994; 344: 1383-9.
2. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
3. Heart Protection Study Collaborative Group: MRC/BHF. Heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
4. Sheperd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemi: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7.
5. Langerdorfer A, Stein EA, Kruyer W, Gotto AMjr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Prevention Study. JAMA 1998; 279: 1615-1622.
6. Matsuda M, Korn BS, Hammer RE, et al. SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver-induced by cholesterol deprivation and insulin elevation. Genes Dev 2001; 15: 1206-16.
7. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiol 1998; 81: 582-7.
8. Lipid Research Clinics Coronary Primary Prevention Trial results. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-74.
9. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45.
10. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clorofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405-18.
11. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323: 946-55.
12. Blankenhorn DH, Azen SP, Kramash DM, et al. Coronary angiographic changes with lovastatin therapy; the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993; 119: 969-76.
13. Jukema JW, Brauschkle AVG, van Bovan AJ, et al. Effects of lipid-lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-40.
14. Hodis HN, Mack WJ, LaBree L, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy. A randomised, controlled clinical trail. Ann Intern Med 1996; 124: 548-56.
15. Libby P. What have we learned about the biology of atherosclerosis?: the role of inflammation. Am J Cardiol 2001; 88: 3-6.
16. Guijarro C, Blanco-Colio LM, Ortego M, et al. 3-hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998; 88: 490-500.
17. Alaei P, MacNulty EE, Ryder NS. Inhibition of protein prenylation down-regulates signalling by inflammatory mediators in human keratinocytes. Biochem Biophys Res Commun 1996; 222: 133-8.
18. Laufs U, Endres M, Custodis F, Gertz K, et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feed-back regulation of Rho GTPase gene transcription. Circulation 2000; 102: 3104-10.
19. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-92.
20. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70.
21. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction of C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191-3.
22. Ridker PM, Rifai N, Clearfield M, Downs JR, et al. Measurements of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-65.
23. Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group: fragmin during instability in coronary artery Disease. N Engl J Med 2000; 343: 1139-47.
24. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher AM, Chaitman, BR, Leslie, S, Stern, T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL Study: a randomized controlled trial. JAMA 2001; 285: 1711-18.
25. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001; 357: 1063-8.
26. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430-6.
27. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-72.
28. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-64.
29. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors I and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999; 103: 879-87.
30. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067-72.
31. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001; 103: 1718-20.
32. Eto M, Kozai T, Cosentino F, et al. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 2002; 105: 1756-9.
33. Guha M, Mackman N. The PI3K-Akt pathway limits LPS activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 2002; 277: 3214-32.
34. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 2002; 90: 1243-50.
35. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 7: 1004-10.
36. Dimmeler S, Aicher A, Vasa, M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001; 108: 391-7.
37. Carrvahlo AC, Colman RW, Less RS. Platelet function in hyperlipoproteinemia. N Engl J Med 1974; 290: 434-8.
38. Cosentino F. L'endotelio: dalla flessibilità funzionale alla malattia cardiovascolare. Roma: Il Pensiero Scientifico Editore 1998.
39. Cox DA, Vita JA, Treasure CB, et al. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation 1989; 80: 458-65.
40. Kern MJ. Coronary physiology revisited: practical insights from the cardiac catheterization laboratory. Circulation 2000; 101: 1344-51.
41. Murakami H, Urabe K, Nishimura M. Inappropriate microvascular constriction produced transient ST-segment elevation in patients with synrome X. J Am Coll Cardiol 1998; 32: 1287-94.
42. Mathier MA, Rose GA, Fifer MA, et al. Coronary endothelial dysfunction in patients with acute - onset idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1998; 32: 216-24.
43. Andrews TC, Raby K, Bazzy J, Naimi CL, Alfred E, Ganz P, Selwyn AP. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997; 95: 324-8.
44. Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone-marrow-derived endothelial progenitor cells. Circulation 2002; 105: 3017-24.
45. Dimmeler S, Aircher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001; 108: 391-7.
46. Vasa M, Fichtscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001; 103: 2885-90.
47. Dimmeler S, Fleming I, Fisshalter B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-5.